Karenitecin
Based on 1 publication(s) in Google Scholar
Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
For research use only. We do not sell to patients.
- Purity : 98.02%
- CAS No.: 203923-89-1
- Formula: C25H28N2O4Si
- Molecular Weight:448.59
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13761
TeniposideTopoisomerase Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-13631
ExatecanTopoisomerase I Inhibitor -
HY-13631A
Exatecan mesylateTopoisomerase I Inhibitor -
HY-13631R
Exatecan (Standard)Topoisomerase I Inhibitor -
HY-15753
EllipticineTopoisomerase Inhibitor -
HY-100309
9-AminocamptothecinTopoisomerase I Inhibitor -
HY-10982
AmonafideTopoisomerase Inhibitor -
HY-13727A
PixantroneTopoisomerase II Inhibitor -
HY-13562A
Banoxantrone dihydrochlorideTopoisomerase II Inhibitor -
HY-13631AG
Exatecan mesylate (GMP)Topoisomerase I Inhibitor -
HY-100875
BisantreneAntitumor Agent
Publications Citing Use of MedChemExpress (MCE) Karenitecin
MoreAll Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
|
Topoisomerase I |
In Vitro
Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC10, IC50, and IC90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration[1]. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC50s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 203923-89-1
-
Appearance Solid
-
Molecular Weight 448.59
-
Formula C25H28N2O4Si
-
Color Light yellow to yellow
-
SMILES
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC[Si](C)(C)C)C5=CC=CC=C5N=C4C3=C2)=O
-
Synonyms
Cositecan; BNP 1350
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 3.03 mg/mL (6.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. [Content Brief]
[2]. Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2292 mL | 11.1460 mL | 22.2921 mL | 55.7302 mL |
| 5 mM | 0.4458 mL | 2.2292 mL | 4.4584 mL | 11.1460 mL |
Karenitecin Related Classifications
HY-14812 Related Classifications
Powered by Bioz